Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial

References

• Murphy RL, Berzins B, Zala C, et al. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS. 2010;24:885–890.10.1097/QAD.0b013e3283352ed5
   PubMed Web of Science ®Google Scholar
• Overton ET, Arathoon E, Baraldi E, Tomaka F. Effect of darunavir on lipid profile in HIV-infected patients. HIV Clin Trials. 2012;13:256–270.10.1310/hct1305-256
   PubMed Web of Science ®Google Scholar
• Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–1193.10.1097/00002030-200305230-00010
   PubMed Web of Science ®Google Scholar
• Friis-Møller N, Ryom L, Smith C, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The data-collection on adverse effects of anti-HIV drugs (D:A:D) study. Eur J Prev Cardiol. 2015. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Kitahata MM, Rodriguez B, Haubrich R, et al. Cohort profile: The centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol. 2008;37:948–955.10.1093/ije/dym231
   PubMed Web of Science ®Google Scholar
• Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63–F70.10.1097/00002030-199907090-00001
   PubMed Web of Science ®Google Scholar
• Flint OP, Noor MA, Hruz PW, et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: Cellular mechanisms and clinical implications. Toxicol Pathol. 2009;37:65–77.10.1177/0192623308327119
   PubMed Web of Science ®Google Scholar
• Stein JH, Komarow L, Cotter BR, et al. Lipoprotein changes in HIV-infected antiretroviral-naïve individuals after starting antiretroviral therapy: ACTG study A5152s Stein: lipoprotein changes on antiretroviral therapy. J Clin Lipidol. 2008;2:464–471.10.1016/j.jacl.2008.08.442
   PubMed Web of Science ®Google Scholar
• Gotti D, Cesana BM, Albini L, et al. Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir. HIV Clin Trials. 2012;13:245–255.10.1310/hct1305-245
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Na LH, Landovitz RJ, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015;60:1842–1851.10.1093/cid/civ193
   PubMed Web of Science ®Google Scholar
• Zhou H, Jarujaron S, Gurley EC, et al. HIV protease inhibitors increase TNF-α and IL-6 expression in macrophages: Involvement of the RNA-binding protein HuR. Atherosclerosis. 2007;195:e134–e143.10.1016/j.atherosclerosis.2007.04.008
   PubMedGoogle Scholar
• Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr. 1999;21:209–216.10.1097/00126334-199907010-00005
   PubMed Web of Science ®Google Scholar
• Dubé MP. Disorders of glucose metabolism in patients infected with Human Immunodeficiency Virus. Clin Infect Dis. 2000;31:1467–1475.10.1086/cid.2000.31.issue-6
   PubMed Web of Science ®Google Scholar
• Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:F167–F173.10.1097/00002030-199815000-00001
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53:323–332.10.1097/QAI.0b013e3181c990bf
   PubMed Web of Science ®Google Scholar
• PREZISTA® (darunavir) [package insert]. Titusville, NJ: Janssen Therapeutics; May 2015.
   Google Scholar
• PREZISTA® (darunavir). EPARs for authorized medicinal products for human use. December 2015.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed June 11, 2015.
   Google Scholar
• Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012;28:1184–1195.10.1089/aid.2011.0327
   PubMed Web of Science ®Google Scholar
• Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabet Care. 2012;35:1605–1610.10.2337/dc11-2339
   PubMed Web of Science ®Google Scholar
• Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med. 2002;19:527–534.10.1046/j.1464-5491.2002.00745.x
   PubMed Web of Science ®Google Scholar
• Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15–E26.
   PubMed Web of Science ®Google Scholar
• Noor MA, Parker RA, O’Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004;18:2137–2144.10.1097/00002030-200411050-00005
   PubMed Web of Science ®Google Scholar
• Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study. AIDS. 2002;16:F1–F8.10.1097/00002030-200203290-00002
   PubMed Web of Science ®Google Scholar
• Dubé MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir‐ritonavir in healthy subjects without HIV infection: A placebo‐controlled trial. Clin Infect Dis. 2008;47:567–574.10.1086/591953
   PubMed Web of Science ®Google Scholar
• Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18:641–649.10.1097/00002030-200403050-00008
   PubMed Web of Science ®Google Scholar
• Busti AJ, Bedimo R, Margolis DM, Hardin DS. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med. 2008;56:539–544.
   PubMed Web of Science ®Google Scholar
• Randell PA, Jackson AG, Boffito M, et al. Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. Antivir Ther. 2010;15:1125–1132.10.3851/IMP1675
   PubMed Web of Science ®Google Scholar
• Blümer RM, van Vonderen MG, Sutinen J, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008;22:227–236.10.1097/QAD.0b013e3282f33557
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214–E223.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646–655.10.1016/S0140-6736(08)61081-8
   PubMed Web of Science ®Google Scholar
• Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985;6:45–86.10.1210/edrv-6-1-45
   PubMed Web of Science ®Google Scholar
• Tomaka F, Lefebvre E, Sekar V, et al. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med. 2009;10:318–327.10.1111/hiv.2009.10.issue-5
   PubMed Web of Science ®Google Scholar